Substituted Indole Derivatives Modulating Gamma-Secretase

The patent applies parameter changes by systematically modifying chemical structures of gamma-secretase modulators, specifically adjusting substituents at positions R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, and R20 to optimize metabolic stability while maintaining therapeutic efficacy. The novel indole derivatives with specific substitution patterns improve pharmacokinetic properties without sacrificing the ability to modulate gamma-secretase activity and reduce amyloid beta peptide levels.

The patent modifies molecular parameters of gamma-secretase modulators to enhance central nervous system penetration. The novel indole derivatives incorporate specific lipophilic substituents and molecular weight optimizations that facilitate blood-brain barrier crossing, thereby improving central brain availability while maintaining the therapeutic effect of reducing amyloid beta peptide levels.

The patent systematically adjusts chemical parameters of the modulators to eliminate cytochrome P450 inhibition. The novel indole derivatives are designed with specific substituent patterns that avoid interaction with CYP enzyme active sites, thereby preventing metabolic inhibition and associated side effects while preserving the therapeutic mechanism of gamma-secretase modulation and amyloid beta reduction.

The patent employs segmentation by dividing the complex molecule into distinct functional modules: a core indole structure with systematically varied substituents at defined positions. This modular approach allows independent optimization of each substituent for metabolic stability, brain penetration, and CYP inhibition avoidance, while maintaining overall molecular coherence and facilitating structure-activity relationship analysis.